Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (201-210 of 208) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 208 results.
European Urology Oncology|December 19, 2025
Predictive Value of Prior Non-muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC CohortElisabeth Grobet-Jeandin, Elliott Diamant, Pierre-Etienne Gabriel, et al.
BJU International|February 7, 2023
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomyFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?<sup>†</sup>Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 16, 2026
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerPietro Scilipoti, Mario de Angelis, Constance Thibault, et al.
Cancer Discovery|August 5, 2022
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder CancerAnne-Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further ResearchShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain TumorsShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Pageof 21

Showing results (201-210 of 208) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 208 results.
European Urology Oncology|December 19, 2025
Predictive Value of Prior Non-muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC CohortElisabeth Grobet-Jeandin, Elliott Diamant, Pierre-Etienne Gabriel, et al.
BJU International|February 7, 2023
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomyFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?<sup>†</sup>Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 16, 2026
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerPietro Scilipoti, Mario de Angelis, Constance Thibault, et al.
Cancer Discovery|August 5, 2022
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder CancerAnne-Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further ResearchShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain TumorsShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Pageof 21